Ox66™ - a Novel COVID-19 Therapeutic
Hemotek, LLC, Plano, Texas, United States
Technologies for improved delivery of supplemental oxygen
Tech Brief: Ox66™ is a novel, non-gaseous form of "powdered oxygen"; the compound is composed of approximately 66.2% oxygen, contained in a clathrate of Al(OH)3. When consumed, oxygen is released via the circulatory system, quickly oxygenating cells, tissues, and organs bypassing the COVID-19 compromised respiratory system. Preclinically tested, effective, non-toxic, in production.
Mid-stage Startup (A or B)
FIGURES OF MERIT Value Proposition: The healthcare sector will experience both short and long-term disruption by this technology as well as numerous commercial markets. There is basic equity available in the holding company. There will be commercial licenses available to market Ox66™ as a stand-alone solution or in combination with an existing product to increase efficacy; Joint Venture possibilities; and philanthropic opportunities to accelerate R&D for Ox66™ solutions. Based on current capacity plans, Ox66™ could treat over 1m people in 2021, 7.5m in 2022, and over 20m people in 2023 with potential revenue of +$6.4B, limited only by manufacturing capacity. Currently over 65.8m people globally have been afflicted by the virus, with over 1.5m deaths. Beyond COVID-19, there are several other medical Indications and non-medical markets for Ox66™ as every human, animal, and plant require oxygen to survive. Hemotek has 36 patents (21 issued, 15 pending) that cover non-medical markets from Cosmetics, Skincare, Energy/Performance drinks, Agriculture, Nutritional Supplements, Water Treatment, Fuel Additive to medical Indications for Wound/Burn Care, TBI, Resuscitation Fluid, Viruses like African Swine Fever, HIV, Ebola, and a host of Respiratory issues like COPD and asthma.